News & Updates

Fred Aswad 12/4/25 Fred Aswad 12/4/25

Apeiron Therapeutics Presents First-in-Human Data from Phase 1 Clinical Trial of GTA182 in MTAP-Deleted Advanced Non-Small Cell Lung Cancer at the ESMO Asia Congress 2025

Fred Aswad 11/23/25 Fred Aswad 11/23/25

Apeiron Therapeutics to Present FiH Phase 1 Data on PRMT5 Inhibitor GTA182 at ESMO Asia 2025

Guest User 4/25/25 Guest User 4/25/25

Apeiron Therapeutics Presents Preclinical Data from its Oncology Program on PRMT5 Inhibitor GTA182 at AACR 2025 Annual Meeting

Guest User 3/25/25 Guest User 3/25/25

Apeiron Therapeutics to Present Preclinical Data on PRMT5 Inhibitor GTA182 at AACR 2025 Annual Meeting

Guest User 11/18/24 Guest User 11/18/24

Apeiron Enrolls First Patient in Phase 1a/b Study of PRMT5 Inhibitor GTA182 for MTAP-Deleted Solid Tumors

Fred Aswad 10/13/24 Fred Aswad 10/13/24

Apeiron Receives IND Clearance from NMPA for next generation PRMT5 Inhibitor GTA182 to Treat MTAP Null Tumors

Fred Aswad 7/18/24 Fred Aswad 7/18/24

Apeiron to Expand Investment in Synthetic Lethality Pipeline After New Phase in Collaboration with Exscientia

Fred Aswad 10/17/23 Fred Aswad 10/17/23

GT Apeiron Announces Development Candidate Nomination of Brain Penetrant PRMT5 Inhibitor, GTA182, for the Potential Treatment of MTAP-Deleted Solid Cancers

Fred Aswad 7/10/23 Fred Aswad 7/10/23

GT Apeiron Announces Enrollment of First Patient in Phase 1/2 “ELUCIDATE” Clinical Trial of CDK7 Inhibitor, GTAEXS617, in Advanced Solid Tumors

Fred Aswad 4/7/23 Fred Aswad 4/7/23

Apeiron will present the latest research on KIF18A at AACR 2023

Fred Aswad 10/27/22 Fred Aswad 10/27/22

Exscientia Presents Novel Patient Stratification and Biomarker Data for GTAEXS-617 at the 34th EORTC-NCI-AACR Annual Symposium

Fred Aswad 3/29/22 Fred Aswad 3/29/22

Apeiron Closes $17.5 Million Series A and Launches Strategic Partnerships

Fred Aswad 3/18/22 Fred Aswad 3/18/22

Apeiron is making its debut at AACR

Fred Aswad 7/21/21 Fred Aswad 7/21/21

Exscientia and GT Apeiron Therapeutics Enter Oncology Joint Venture

Fred Aswad 4/16/21 Fred Aswad 4/16/21

GT Apeiron Therapeutics Strengthens Advisory Board

Fred Aswad 2/1/20 Fred Aswad 2/1/20

Apeiron Therapeutics opens US headquarter

Fred Aswad 6/1/19 Fred Aswad 6/1/19

Apeiron founded and announces its partnership with Exscientia